Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Weighs Next Move After Appellate Court Rebuffs Patent Delisting Policy

Executive Summary

FDA is assessing its next step following an appeals court ruling confirming that the agency's position on delisting patents is inconsistent with Hatch/Waxman

You may also be interested in...



Teva Asks FDA To Relist Risperdal Patent And Restore 180-Day Exclusivity

J&J's delisted Risperdal patent should be returned to the "Orange Book" and 180-day exclusivity restored to Teva Pharmaceuticals, the generic company states in a petition to FDA

Teva Asks FDA To Relist Risperdal Patent And Restore 180-Day Exclusivity

J&J's delisted Risperdal patent should be returned to the "Orange Book" and 180-day exclusivity restored to Teva Pharmaceuticals, the generic company states in a petition to FDA

Zocor Exclusivity: Ranbaxy Needs Quick Win In Suit Seeking Patent Re-Listing

Ranbaxy needs a relatively quick win in its lawsuit against FDA if it hopes to benefit from the 180-day exclusivity it is claiming for Zocor 80 mg

UsernamePublicRestriction

Register

MT142726

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel